Latest Funding News

Bounty Oil and Gas reported $1.09 million in oil revenue for FY 2025, boosted reserves to 313,000 barrels, and plans to double production with Surat Basin operations starting late 2025. Meanwhile, a Federal Court challenge looms over its Sydney Basin offshore permit.

Pioneer Lithium advances uranium exploration with promising high-grade assays at Skull Creek, while pausing lithium activities amid market downturn. A recent $320,000 capital raise supports ongoing uranium projects in the US and Namibia.

Resources & Energy Group Limited (REZ) reports strong progress in gold production at East Menzies with two successful gold pours and a $1.1 million capital raise, while divesting its Mount Mackenzie asset to sharpen focus on Western Australia.

Wellnex Life Limited reported a robust Q4 FY25 with a 22% sales increase and positive operational cash flow, underpinning its strategic growth initiatives backed by new debt funding.

Admiralty Resources NL reported a cash balance of $1.738 million at the end of June 2025, supported by financing facilities that provide nearly seven quarters of operational funding. The company’s latest cash flow report reveals ongoing investment in exploration alongside careful management of its loan facilities.

West Cobar Metals has completed the acquisition of the Mystique Gold Project in Western Australia and reported a maiden inferred mineral resource at its Bulla Park copper-antimony deposit in New South Wales, while drilling assays from its Fraser Range copper-gold targets are pending.

Pacific Lime and Cement Limited has made significant strides in Papua New Guinea, rebranding and advancing key projects while initiating commercial quicklime shipments to Western Australia. The company’s robust cash position and community agreements set the stage for upcoming construction milestones.

Quantum Graphite Limited has made significant strides in developing its Eyre Peninsula Graphite Hub, progressing detailed planning with government stakeholders and attracting new financiers for its Uley 2 project. Exploration and purification testwork updates promise to refine its resource and product quality outlook.

Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Health and Plant Protein Group Ltd (HPP) ended FY25 Q4 with a strong cash position following a significant IRS payment, while signaling plans for shareholder returns and confidential corporate opportunities.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.